Ascendis Pharma A (ASND) Revenue (2012 - 2026)

Ascendis Pharma A has disclosed Revenue across 14 years of filings, most recently posting $288.7 million for Q1 2026.

• Revenue for Q1 2026 came in at $288.7 million, up 171.87% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.1 billion (up 129.54% YoY), and the FY2025 annual result was $838.3 million, up 93.32% from the prior year.
• Revenue came in at $288.7 million for Q1 2026 at Ascendis Pharma A, down from $380.4 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $380.4 million in Q4 2025 to a low of $6.6 million in Q2 2022.
• The 5-year median for Revenue is $63.5 million (2024), against an average of $125.6 million.
• Peak annual rise in Revenue reached 1074.55% in 2022, while the deepest fall reached 73.68% in 2022.
• Ascendis Pharma A's Revenue stood at $23.4 million in 2022, then soared by 1019.31% to $261.5 million in 2023, then gained by 3.18% to $269.8 million in 2024, then surged by 41.0% to $380.4 million in 2025, then slipped by 24.1% to $288.7 million in 2026.
• The last three Revenue figures came in at $288.7 million (Q1 2026), $380.4 million (Q4 2025), and $249.7 million (Q3 2025), per Business Quant data.